Tissue Platinum Concentration and Tumor Response in Non-small-cell Lung Cancer

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2012 Aug 15

PMID 22891266

Citations 44

Authors

Eric S Kim

J Jack Lee

Guangan He

Chi-Wan Chow

Junya Fujimoto

Neda Kalhor

Stephen G Swisher

Ignacio I Wistuba

David J Stewart

Zahid H Siddik

Affiliations

Soon will be listed here.

Abstract

Purpose: Platinum resistance is a major limitation in the treatment of advanced non-small-cell lung cancer (NSCLC). Reduced intracellular drug accumulation is one of the most consistently identified features of platinum-resistant cell lines, but clinical data are limited. We assessed the effects of tissue platinum concentrations on response and survival in NSCLC.

Patients And Methods: We measured total platinum concentrations by flameless atomic absorption spectrophotometry in 44 archived fresh-frozen NSCLC specimens from patients who underwent surgical resection after neoadjuvant platinum-based chemotherapy. Tissue platinum concentration was correlated with percent reduction in tumor size on post- versus prechemotherapy computed tomography scans. The relationship between tissue platinum concentration and survival was assessed by univariate and multicovariate Cox proportional hazards regression model analysis and Kaplan-Meier analysis.

Results: Tissue platinum concentration correlated significantly with percent reduction in tumor size (P < .001). The same correlations were seen with cisplatin, carboplatin, and all histology subgroups. Furthermore, there was no significant impact of potential variables such as number of cycles and time lapse from last chemotherapy on platinum concentration. Patients with higher platinum concentration had longer time to recurrence (P = .034), progression-free survival (P = .018), and overall survival (P = .005) in the multicovariate Cox model analysis after adjusting for number of cycles.

Conclusion: This clinical study established a relationship between tissue platinum concentration and response in NSCLC. It suggests that reduced platinum accumulation might be an important mechanism of platinum resistance in the clinical setting. Further studies investigating factors that modulate intracellular platinum concentration are warranted.

Citing Articles

Genetic Navigation: A Narrative Review of XRCC1 Polymorphism Impact on Platinum-Based Chemotherapy Outcomes in NSCLC Patients.

Permatasari L, Afifah N, Ishmatullah M, Intania R, Halimah E, Barliana M Cancer Manag Res. 2025; 17:383-395.

PMID: 40034865 PMC: 11874740. DOI: 10.2147/CMAR.S501420.

Drug-Eluting Beads Bronchial Arterial Chemoembolization Combined with Immunotherapy Resulted in Pathological Complete Response of Squamous Cell Lung Cancer: A Case Report.

He G, Yang K, Gao Z, Zhang X, Han A Int Med Case Rep J. 2024; 17:1041-1047.

PMID: 39723431 PMC: 11668917. DOI: 10.2147/IMCRJ.S491862.

Shenqi Fuzheng Injection Reduces Cisplatin-Induced Kidney Injury via cGAS/STING Signaling Pathway in Breast Cancer Mice Model.

Ma Y, Bai B, Liu D, Shi R, Zhou Q Breast Cancer (Dove Med Press). 2024; 16:451-469.

PMID: 39165276 PMC: 11335009. DOI: 10.2147/BCTT.S475860.

Reprogramming exosomes for immunity-remodeled photodynamic therapy against non-small cell lung cancer.

Guo J, Zhao W, Xiao X, Liu S, Liu L, Zhang L Bioact Mater. 2024; 39:206-223.

PMID: 38827172 PMC: 11141154. DOI: 10.1016/j.bioactmat.2024.05.030.

Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.

Sito H, Tan S Mol Biol Rep. 2024; 51(1):102.

PMID: 38217759 DOI: 10.1007/s11033-023-08915-2.

References

Gregg R, Molepo J, Monpetit V, Mikael N, Redmond D, Gadia M . Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol. 1992; 10(5):795-803. DOI: 10.1200/JCO.1992.10.5.795. View

Stewart D, Raaphorst G, Yau J, Beaubien A . Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs. 1996; 14(2):115-30. DOI: 10.1007/BF00210782. View

Hoang T, Xu R, Schiller J, Bonomi P, Johnson D . Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol. 2004; 23(1):175-83. DOI: 10.1200/JCO.2005.04.177. View

Ikuta K, Takemura K, Sasaki K, Kihara M, Nishimura M, Ueda N . Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol Pharm Bull. 2005; 28(4):707-12. DOI: 10.1248/bpb.28.707. View

Nakagawa T, Inoue Y, Kodama H, Yamazaki H, Kawai K, Suemizu H . Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Oncol Rep. 2008; 20(2):265-70. View

Koukourakis M, Giatromanolaki A, Sivridis E . Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol. 2003; 24(4):199-202. DOI: 10.1159/000074430. View

Chen H, Yan J, Chen W, Kuo M, Lai Y, Lai W . Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer. 2011; 75(2):228-34. PMC: 3319119. DOI: 10.1016/j.lungcan.2011.06.011. View

Komatsu M, Sumizawa T, Mutoh M, Chen Z, Terada K, Furukawa T . Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res. 2000; 60(5):1312-6. View

Bungo M, Fujiwara Y, Kasahara K, Nakagawa K, Ohe Y, Sasaki Y . Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res. 1990; 50(9):2549-53. View

10.

Los G, Verdegaal E, Noteborn H, Ruevekamp M, de Graeff A, Meesters E . Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. Biochem Pharmacol. 1991; 42(2):357-63. DOI: 10.1016/0006-2952(91)90723-i. View

11.

Stewart D, Benjamin R, Luna M, Feun L, Caprioli R, Seifert W . Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol. 1982; 10(1):51-4. DOI: 10.1007/BF00257239. View

12.

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

13.

Stewart D, Mikhael N, Nair R, Kacew S, Montpetit V, Nanji A . Platinum concentrations in human autopsy tumor samples. Am J Clin Oncol. 1988; 11(2):152-8. DOI: 10.1097/00000421-198804000-00013. View

14.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

15.

Stewart D, Dulberg C, Molepo J, Mikhael N, Montpetit V, Redmond M . Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration. Cancer Chemother Pharmacol. 1994; 34(1):14-22. DOI: 10.1007/BF00686106. View

16.

Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C, Hara N . Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer. 1998; 34(9):1352-7. DOI: 10.1016/s0959-8049(98)00067-7. View

17.

Stewart D, Chiritescu G, Dahrouge S, Banerjee S, Tomiak E . Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev. 2007; 33(2):101-37. DOI: 10.1016/j.ctrv.2006.12.002. View

18.

Oguri T, Isobe T, Fujitaka K, Ishikawa N, Kohno N . Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer. Int J Cancer. 2001; 93(4):584-9. DOI: 10.1002/ijc.1369. View

19.

Stewart D . Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol. 2010; 75(3):173-234. PMC: 2888634. DOI: 10.1016/j.critrevonc.2009.11.006. View

20.

Vergote I, Trope C, Amant F, Kristensen G, Ehlen T, Johnson N . Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363(10):943-53. DOI: 10.1056/NEJMoa0908806. View